Biotech News
Related news
RHHBYRoche Holdings AG2026-10-16 05:00 EST
FDA approves Roche’s Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)
BNTCBenitec Biopharma2026-10-05 12:00 EST
Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study
ABUSArbutus2026-10-01 11:30 EST
Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
ABUSArbutus2026-09-30 11:30 EST
Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
RHHBYRoche Holdings AG2026-09-30 05:00 EST
Roche’s fenebrutinib is the first BTK inhibitor to receive U.S. FDA filing acceptance in both relapsing and primary progressive multiple sclerosis
JNJJohnson & Johnson2026-09-21 14:33 EST
European Commission approval of ICOTYDE™▼(icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide
PHARPharming Group2026-09-11 18:00 EST
FDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S.
BNTXBioNTech2026-08-27 20:30 EST
Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
JNJJohnson & Johnson2026-10-23 11:09 EST
European Commission approves Johnson & Johnson’s TECVAYLI®▼ (teclistamab) monotherapy for relapsed/refractory multiple myeloma, expanding treatment options from first relapse
PHARPharming Group2026-09-25 14:30 EST
Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS
Arbutus
Hepatitis B Therapeutics Arbutus Biopharma develops therapies intended to achieve a functional cure for chronic hepatitis B. Its current clinical strategy centers on suppressing viral antigen production with RNA interference. Imdusiran Imdusiran is an RNA interference therapeutic that reduces production of hepatitis B viral proteins,...
Recent company news
ABUSArbutus2026-10-22 11:30 EST
Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor
ABUSArbutus2026-10-01 11:30 EST
Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
ABUSArbutus2026-09-30 11:30 EST
Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
ABUSArbutus2026-08-24 11:30 EST
Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share
ABUSArbutus2026-08-21 11:30 EST
Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer
Stock data
- Close
- 4.21 USD
- Market cap
- 841.51M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States